Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05180773 · ClinicalTrials.gov registry record · Phase 4
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
A Phase 4 study of Peripartum Cardiomyopathy, Postpartum, sponsored by Dennis M. McNamara, MD, MS.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 250
- Enrollment target
- 20
- Study locations
NCT05180773 is a Phase 4 study of Peripartum Cardiomyopathy, Postpartum that is actively recruiting participants, run by Dennis M. McNamara, MD, MS. The registered enrollment target is 250 participants. The trial reports 20 study locations across 11 states.
The verdict
NCT05180773, a Phase 4 study of Peripartum Cardiomyopathy, Postpartum, is actively recruiting participants, sponsored by Dennis M. McNamara, MD, MS.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 250 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized placebo controlled trial of bromocriptine therapy to evaluate its impact on myocardial recovery and clinical outcomes. Given that bromocriptine prevents breastfeeding, an additional 50 women with peripartum cardiomyopathy excluded from the trial due to a desire to continue breastfeeding but meeting all other entry criteria will be followed in an observational cohort.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Bromocriptine
- DRUG Guideline Directed Medical Therapy for Heart Failure (GDMT)
- DRUG Rivaroxaban
- DRUG Second Placebo
Study Locations (20)
California
- University of California San Diego - La Jolla
- Keck School of Medicine of USC - Los Angeles
- Cedars-Sinai Medical Center - Los Angeles
- University of California Irvine Health - Orange
- Stanford University - Stanford
Florida
- University of Florida - Gainesville
- Mayo Clinic, Florida - Jacksonville
- University of South Florida - Tampa
Connecticut
- Hartford Hospital - Hartford
- Yale University - New Haven
Illinois
- Northwestern University - Chicago
- University of Illinois Health Heart Center - Chicago
Indiana
- Indiana University/Indiana University Health - Indianapolis
- Ascension St. Vincent Heart Center - Indianapolis
Alabama
- University of Alabama Birmingham - Birmingham
Arizona
- University of Arizona Sarver Heart Center - Tucson
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2022-07-27 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05180773
The ClinicalTrials.gov registry entry for NCT05180773 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dennis M. McNamara, MD, MS, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Peripartum Cardiomyopathy, Postpartum appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT05180773 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Connecticut.
Frequently Asked Questions
What is clinical trial NCT05180773 about?
NCT05180773 is a clinical study titled "Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy". The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized placebo controlled trial of bromocriptine therapy to evaluate its impact on myocardial recovery and clinical outcomes. Given that bromocriptine prevents breastfeeding, an additio...
What is the current status of trial NCT05180773?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 250 participants. The study started on 2022-07-27. Estimated completion is 2028-12-31.
What conditions does trial NCT05180773 study?
This clinical trial studies the following conditions: Peripartum Cardiomyopathy, Postpartum.
What interventions are being tested in trial NCT05180773?
The interventions under investigation include: Placebo (DRUG), Bromocriptine (DRUG), Guideline Directed Medical Therapy for Heart Failure (GDMT) (DRUG), Rivaroxaban (DRUG), Second Placebo (DRUG).
Who is sponsoring clinical trial NCT05180773?
This trial is sponsored by Dennis M. McNamara, MD, MS, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05180773 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.